Limits...
Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.

Akaza H, Hinotsu S, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M - Prostate Int (2013)

Bottom Line: MAB for prostate cancer patients with intermediate- or high-risk disease has a significant benefit in terms of overall survival compared with LHRH analog monotherapy or surgical castration alone.Better results may be achieved in older (≥75 years) patients.MAB therapy may provide significant survival benefits in intermediate- and high-risk patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

ABSTRACT

Purpose: To determine the influence of maximal androgen blockade (MAB) and non-MAB hormonal therapy with an luteinizing hormone releasing hormone (LHRH) analog on overall survival of prostate cancer patients in the Japan Study Group of Prostate Cancer (J-CaP) registry according to risk, as assessed using the novel J-CAPRA risk instrument. To undertake a multivariate analysis combining J-CAPRA risk score, type of hormonal therapy and comorbidities, in order to assess their impact on overall survival.

Methods: The J-CaP database includes men in Japan diagnosed with any stage of prostate cancer between 2001 and 2003 and treated with primary androgen deprivation therapy (PADT), as monotherapy or in combination. A total of 26,272 men were enrolled and of these 19,265 were treated with PADT. This analysis was undertaken using the latest data set (30 April, 2010) including a total of 15,727 patients who received PADT and had follow-up data for periods ranging from 0 to 9.2 years.

Results: MAB for prostate cancer patients with intermediate- or high-risk disease has a significant benefit in terms of overall survival compared with LHRH analog monotherapy or surgical castration alone. Better results may be achieved in older (≥75 years) patients. Patient comorbidities are an important factor in determining overall survival, notably in older patients, and should be considered when selecting therapy.

Conclusions: Based on large-scale registry data, this report is the first to analyze the outcomes of MAB therapy in patients with prostate cancer at a wide range of disease stages. MAB therapy may provide significant survival benefits in intermediate- and high-risk patients.

No MeSH data available.


Related in: MedlinePlus

Overall survival according to J-CAPRA risk score for three age groups of patients (≤65 [A], 66–75 [B], and >75 years of age [C]) who received primary androgen deprivation therapy (PADT) (P<0.0001). J-CAPRA score: low (0–2, blue), intermediate (3–7, red), high (8+, green).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3814111&req=5

f2-pi_1-2-81-06: Overall survival according to J-CAPRA risk score for three age groups of patients (≤65 [A], 66–75 [B], and >75 years of age [C]) who received primary androgen deprivation therapy (PADT) (P<0.0001). J-CAPRA score: low (0–2, blue), intermediate (3–7, red), high (8+, green).

Mentions: Overall survival according to J-CAPRA risk score for three age groups of patients (≤65, 66–75, and >75 years of age) who received PADT is shown in Fig. 2. When analyzed according to age category, it was found that within each age cohort increasing J-CAPRA risk score was associated with reduced overall survival (P<0.0001). For each J-CAPRA risk group there was a slight tendency to reduced overall survival with increasing age. Overall survival estimates are shown in Table 1.


Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.

Akaza H, Hinotsu S, Usami M, Ogawa O, Kitamura T, Suzuki K, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M - Prostate Int (2013)

Overall survival according to J-CAPRA risk score for three age groups of patients (≤65 [A], 66–75 [B], and >75 years of age [C]) who received primary androgen deprivation therapy (PADT) (P<0.0001). J-CAPRA score: low (0–2, blue), intermediate (3–7, red), high (8+, green).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3814111&req=5

f2-pi_1-2-81-06: Overall survival according to J-CAPRA risk score for three age groups of patients (≤65 [A], 66–75 [B], and >75 years of age [C]) who received primary androgen deprivation therapy (PADT) (P<0.0001). J-CAPRA score: low (0–2, blue), intermediate (3–7, red), high (8+, green).
Mentions: Overall survival according to J-CAPRA risk score for three age groups of patients (≤65, 66–75, and >75 years of age) who received PADT is shown in Fig. 2. When analyzed according to age category, it was found that within each age cohort increasing J-CAPRA risk score was associated with reduced overall survival (P<0.0001). For each J-CAPRA risk group there was a slight tendency to reduced overall survival with increasing age. Overall survival estimates are shown in Table 1.

Bottom Line: MAB for prostate cancer patients with intermediate- or high-risk disease has a significant benefit in terms of overall survival compared with LHRH analog monotherapy or surgical castration alone.Better results may be achieved in older (≥75 years) patients.MAB therapy may provide significant survival benefits in intermediate- and high-risk patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Strategic Investigation on Comprehensive Cancer Network Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.

ABSTRACT

Purpose: To determine the influence of maximal androgen blockade (MAB) and non-MAB hormonal therapy with an luteinizing hormone releasing hormone (LHRH) analog on overall survival of prostate cancer patients in the Japan Study Group of Prostate Cancer (J-CaP) registry according to risk, as assessed using the novel J-CAPRA risk instrument. To undertake a multivariate analysis combining J-CAPRA risk score, type of hormonal therapy and comorbidities, in order to assess their impact on overall survival.

Methods: The J-CaP database includes men in Japan diagnosed with any stage of prostate cancer between 2001 and 2003 and treated with primary androgen deprivation therapy (PADT), as monotherapy or in combination. A total of 26,272 men were enrolled and of these 19,265 were treated with PADT. This analysis was undertaken using the latest data set (30 April, 2010) including a total of 15,727 patients who received PADT and had follow-up data for periods ranging from 0 to 9.2 years.

Results: MAB for prostate cancer patients with intermediate- or high-risk disease has a significant benefit in terms of overall survival compared with LHRH analog monotherapy or surgical castration alone. Better results may be achieved in older (≥75 years) patients. Patient comorbidities are an important factor in determining overall survival, notably in older patients, and should be considered when selecting therapy.

Conclusions: Based on large-scale registry data, this report is the first to analyze the outcomes of MAB therapy in patients with prostate cancer at a wide range of disease stages. MAB therapy may provide significant survival benefits in intermediate- and high-risk patients.

No MeSH data available.


Related in: MedlinePlus